Loading clinical trials...
Loading clinical trials...
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Conditions
Interventions
Daratumumab
Bortezomib
+5 more
Locations
64
United States
Cancer Center of Central Connecticut - Southington
Southington, Connecticut, United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
UF Health Cancer Center at Orlando Health
Orlando, Florida, United States
Karmonos Cancer Institute
Detroit, Michigan, United States
Providence Cancer Center
Southfield, Michigan, United States
Billings Clinic
Billings, Montana, United States
Start Date
April 26, 2018
Primary Completion Date
August 12, 2020
Completion Date
April 18, 2024
Last Updated
April 29, 2025
NCT06679101
NCT05969860
NCT06057402
NCT06383143
NCT06870760
NCT07523555
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions